๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes

โœ Scribed by Sheilaine R. Mabanta; William M. Mendenhall; Scott P. Stringer; Nicholas J. Cassisi


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
72 KB
Volume
21
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background. To analyze the likelihood of salvage for patients with recurrence in the neck after radiotherapy.

Method. Recurrent disease developed in the neck of 51 patients after primary irradiation for head and neck carcinoma. Salvage was defined as no recurrence of cancer anywhere for at least 1 year after initial salvage treatment and continuously thereafter.

Results. Thirty-three patients (65%) did not undergo a salvage attempt: 18 had unresectable disease; 9 were medically unfit, 4 had distant metastasis; and 2 refused treatment. Eighteen patients (35%) underwent salvage treatment with chemotherapy alone (4 patients), chemotherapy and neck dissection (1 patient), neck dissection alone (11 patients), or surgery with radiotherapy (2 patients). After the initial salvage treatment, recurrent localregional and/or distant disease developed in all patients. Recurrence was in the neck alone in 10 patients (55%); neck and distant sites in 3 patients (17%); neck, primary site, and distant sites in 2 patients (11%); and with distant metastasis alone in 3 patients (17%). Control of neck disease at 5 years was 9% for the 18 patients who underwent a salvage attempt, as well as for all 51 patients. For the overall group, absolute and cause-specific survival rates were both 10% at 5 years.

Conclusions. The likelihood of successful salvage treatment after a neck recurrence following radiotherapy is remote.


๐Ÿ“œ SIMILAR VOLUMES


Paclitaxel, cisplatin, and 5-fluorouraci
โœ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB ๐Ÿ‘ 1 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi